Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Federico

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Chemmedchem|September 7, 2023
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A<sub>3</sub> Adenosine Receptors in Cancer Cell LinesStephanie Federico, Margherita Persico, Letizia Trevisan, et al.
European Journal of Medicinal Chemistry|March 15, 2021
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systemsIlenia Grieco, Maicol Bissaro, Davide Benedetto Tiz, et al.
Molecules (Basel, Switzerland)|October 17, 2019
Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer TherapyAaron Tan, Maria V Babak, Gopalakrishnan Venkatesan, et al.
Chemmedchem|December 15, 2018
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic InhibitionSara Redenti, Irene Marcovich, Teresa De Vita, et al.
Plos One|January 6, 2018
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatmentYi-Ming Shao, Xiaohua Ma, Priyankar Paira, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
"Dual Anta-Inhibitors" of the A<sub>2A</sub> Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling StudiesAndrea Spinaci, Michela Buccioni, Daniela Catarzi, et al.
ACS Chemical Neuroscience|July 22, 2022
Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral SclerosisClaudia Albertini, Alessandra Salerno, Silvia Atzeni, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Chemmedchem|September 7, 2023
[1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A<sub>3</sub> Adenosine Receptors in Cancer Cell LinesStephanie Federico, Margherita Persico, Letizia Trevisan, et al.
European Journal of Medicinal Chemistry|March 15, 2021
Developing novel classes of protein kinase CK1δ inhibitors by fusing [1,2,4]triazole with different bicyclic heteroaromatic systemsIlenia Grieco, Maicol Bissaro, Davide Benedetto Tiz, et al.
Molecules (Basel, Switzerland)|October 17, 2019
Design, Synthesis and Evaluation of New Indolylpyrimidylpiperazines for Gastrointestinal Cancer TherapyAaron Tan, Maria V Babak, Gopalakrishnan Venkatesan, et al.
Chemmedchem|December 15, 2018
A Triazolotriazine-Based Dual GSK-3β/CK-1δ Ligand as a Potential Neuroprotective Agent Presenting Two Different Mechanisms of Enzymatic InhibitionSara Redenti, Irene Marcovich, Teresa De Vita, et al.
Plos One|January 6, 2018
Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatmentYi-Ming Shao, Xiaohua Ma, Priyankar Paira, et al.
Pharmaceuticals (Basel, Switzerland)|June 1, 2023
"Dual Anta-Inhibitors" of the A<sub>2A</sub> Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling StudiesAndrea Spinaci, Michela Buccioni, Daniela Catarzi, et al.
ACS Chemical Neuroscience|July 22, 2022
Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral SclerosisClaudia Albertini, Alessandra Salerno, Silvia Atzeni, et al.
Pageof 6